Objective:

To evaluate the performance of AI models for predicting EGFR in lung adenocarcinoma, focusing on their effectiveness in diverse patient populations.

Approach:

• Study Evaluation: The article discusses the study by Rakaee et al. that evaluates AI models for EGFR prediction, noting performance issues specifically in Asian patients and pleural samples.
• Concerns Raised: It highlights the necessity for validation frameworks that are aware of ancestry and tissue context for AI pathology models.
• Proposed Solutions: Proposals include performance reporting across ancestral groups, the creation of diverse benchmarking datasets, and ongoing monitoring after deployment.

Key Findings:

• The AI model EAGLE showed significant performance degradation in Asian patients (AUC 0.68) and pleural samples (AUC 0.66).
• Ancestry-associated morphologic variation and specimen context influence algorithm behavior.
• The decline in performance for Asian patients persisted despite higher EGFR variant prevalence.

Interpretation:

The findings indicate a risk of exacerbating healthcare disparities if AI tools are deployed without adequate validation across diverse populations.

Limitations:

• The study identifies the absence of subgroup-specific validation in existing AI models.
• There is a risk of healthcare disparities if AI tools are not validated for various ancestries.

Conclusion:

Validation frameworks for AI tools in healthcare must be improved to ensure equitable benefits across diverse populations.

Sources:

• Rakaee et al. Study